Clean Yield Group Cuts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Clean Yield Group trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,756 shares of the medical research company’s stock after selling 32 shares during the quarter. Clean Yield Group’s holdings in Thermo Fisher Scientific were worth $1,371,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. Sivia Capital Partners LLC raised its stake in shares of Thermo Fisher Scientific by 21.6% during the 1st quarter. Sivia Capital Partners LLC now owns 891 shares of the medical research company’s stock worth $443,000 after purchasing an additional 158 shares during the period. Perkins Coie Trust Co raised its stake in shares of Thermo Fisher Scientific by 240.0% during the 1st quarter. Perkins Coie Trust Co now owns 425 shares of the medical research company’s stock worth $211,000 after purchasing an additional 300 shares during the period. WealthBridge Investment Counsel Inc. raised its stake in shares of Thermo Fisher Scientific by 2.4% during the 1st quarter. WealthBridge Investment Counsel Inc. now owns 11,487 shares of the medical research company’s stock worth $5,716,000 after purchasing an additional 265 shares during the period. Intergy Private Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 5.8% during the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company’s stock worth $208,000 after purchasing an additional 23 shares during the period. Finally, Reliant Investment Management LLC raised its stake in shares of Thermo Fisher Scientific by 0.7% during the 1st quarter. Reliant Investment Management LLC now owns 12,336 shares of the medical research company’s stock worth $6,138,000 after purchasing an additional 90 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TMO. Scotiabank lowered their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a research note on Friday, April 25th. Evercore ISI lowered their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Argus lowered their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research note on Tuesday, April 29th. Barclays lowered their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. Finally, The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 23rd. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $605.30.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their position. The disclosure for this sale can be found here. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Up 0.9%

TMO stock opened at $401.99 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company’s 50 day moving average is $420.74 and its 200 day moving average is $495.81. The stock has a market cap of $151.75 billion, a price-to-earnings ratio of 24.32, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business earned $5.11 earnings per share. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.